Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 20.7 CHF 7.14%
Market Cap: 413.2m CHF

Intrinsic Value

The intrinsic value of one NWRN stock under the Base Case scenario is 10.39 CHF. Compared to the current market price of 20.7 CHF, Newron Pharmaceuticals SpA is Overvalued by 50%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NWRN Intrinsic Value
10.39 CHF
Overvaluation 50%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Newron Pharmaceuticals SpA

What is Valuation History?
Ask AI Assistant
What other research platforms think about NWRN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NWRN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Newron Pharmaceuticals SpA.

Explain Valuation
Compare NWRN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NWRN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Newron Pharmaceuticals SpA

Current Assets 61.1m
Cash & Short-Term Investments 9.8m
Receivables 47.1m
Other Current Assets 4.2m
Non-Current Assets 2.8m
PP&E 834k
Other Non-Current Assets 2m
Current Liabilities 23.5m
Accounts Payable 2.5m
Accrued Liabilities 4.9m
Other Current Liabilities 16.1m
Non-Current Liabilities 38.9m
Long-Term Debt 36.9m
Other Non-Current Liabilities 2m
Efficiency

Free Cash Flow Analysis
Newron Pharmaceuticals SpA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Newron Pharmaceuticals SpA

Revenue
51.4m EUR
Cost of Revenue
-892k EUR
Gross Profit
50.5m EUR
Operating Expenses
-24.3m EUR
Operating Income
26.2m EUR
Other Expenses
-10.3m EUR
Net Income
15.8m EUR
Fundamental Scores

NWRN Profitability Score
Profitability Due Diligence

Newron Pharmaceuticals SpA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Exceptional ROIC
Exceptional Operating Margin
ROIC is Increasing
Exceptional Gross Margin
48/100
Profitability
Score

Newron Pharmaceuticals SpA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

NWRN Solvency Score
Solvency Due Diligence

Newron Pharmaceuticals SpA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Short-Term Solvency
Long-Term Solvency
57/100
Solvency
Score

Newron Pharmaceuticals SpA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 18.62 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

Lowest
Price Target
11.62 CHF
44% Downside
Average
Price Target
18.62 CHF
10% Downside
Highest
Price Target
26.25 CHF
27% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Newron Pharmaceuticals SpA
does not pay dividends
Shareholder Yield

Current shareholder yield for NWRN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one NWRN stock?

The intrinsic value of one NWRN stock under the Base Case scenario is 10.39 CHF.

Is NWRN stock undervalued or overvalued?

Compared to the current market price of 20.7 CHF, Newron Pharmaceuticals SpA is Overvalued by 50%.

Back to Top